LEADERSHIP

Makis joined Innovis Pharma in 2018 as President & Managing Director. Prior to that he served for many years as Country Manager for Teva Greece & Cyprus (previously Specifar Pharmaceuticals).

His long tenure in Specifar started in the position of Corporate Development Director, preceding the acquisition of the company by Watson Pharmaceuticals. He was then appointed head of the group upon its merger with Actavis Pharmaceuticals and led the Greek affiliate during all the M&A developments that followed (Allergan, Teva). Before that he was leading Opinion S.A., a marketing research agency, as Managing Partner.

Makis holds a BSc. in Business Administration from Boston University and an MSc. in Corporate Finance from Bentley University.

Vassilis joined Innovis Pharma in 2018 as CFO, moving from Astellas Pharmaceuticals where he held the same role.

Holding a long professional experience in a broad range of industries, Vassilis has held various senior management positions in Greek as well as multinational companies, including Arthur Andersen, PWC, Plaisio Computers, Public World, Inform Lykos, CR Bard, St. Jude Medical as well as Henry Dunant Hospital Center.

Vassilis is a graduate of Business Administration of the University of Macedonia, of Maritime studies from the University of Piraeus and of the Association of Chartered Certified Accountants (ACCA).

Eirini joined Innovis Pharma in 2017 as Head of Scientific Affairs.

She started her career in the pharmaceutical industry at Specifar Pharmaceuticals in 2003, essentially building the company’s R&D, RA, IP and Clinical departments. In 2011, following Specifar’s acquisition from Watson Pharmaceuticals, Eirini was assigned the Head of EU Scientific Affairs position, leading the relative activities of the US parent company in Europe.

Eirini holds a University Degree in Pharmaceutical Science and an MSc in Biopharmacy from King’s College London.

With more than 30 years of experience in the pharma industry, Stelios started his career as Commercial Director in Bayer Hellas. In 1994, he joined Pharmathen Group as Sales & Marketing Director eventually becoming the General Manager & President of the BoD of Pharmathen Hellas, a subsidiary of Pharmathen Group. From 2018 he acts as Deputy Managing Director of Innovis Pharma.

Stelios is a graduate of the Department of Statistics & Insurance Science of the University of Piraeus.

Spiros started his 30-year pharma career in Servier Hellas.

Within his next career stop at Specifar Pharmaceuticals (now Teva Greece), he held various commercial positions including acting as Deputy Sales Director and later on Commercial Operations Director, being an integral part of the management team.

In 2017 he became General Manager of newly formed Innovis Health (later integrated into Innovis Pharma) and from 2018 he serves as Commercial Operations Senior Director in Innovis Pharma.

Spiros has an academic background in Education and holds an MBA from the Hellenic Management Association.

With over 30 years of experience in life sciences, George has held multiple senior management positions for MSD, Parke Davis & PN Gerolymatos, overseeing strategic planning, portfolio management, business development and leading commercial business for numerous disease areas in Greece as well as overseas. Prior to joining Innovis Pharma as Director of Portfolio Management, he acted as Portfolio Management Director in Pharmathen, establishing and leading strategic alliances with several business partners.

George holds a BSc. in Biology from the University of Patras.

Chris joined Innovis Pharma in April 2017 as Gx Portfolio & Sourcing Associate Director with previous relative experience in business development.  Prior to Innovis, Chris was part of Medis’ Business Development team, and had also served Specifar Pharmaceuticals for almost 10 years in various management positions in business development, portfolio, in-licensing as well as exports.  

Before working in the pharma industry, Chris’ academic and extended professional background was in journalism and media.